First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity and studied in patients with cerebral palsy
Pivotal study in cerebral palsy patients with lower limb spasticity aged 2 to 17 showed significant improvements in co-primary efficacy endpoints at Week 4 that evaluated Modified Ashworth Scale in ankle plantar flexor muscle tone and Physician’s Global Assessment response to treatment score.